BioCentury | Jun 29, 2020
Regulation

Intercept: Surrogate endpoint not enough for FDA to approve NASH therapy

...more on Monday; NGM Biopharmaceuticals Inc. (NASDAQ:NGM) slipped 12%, 89bio Inc. (NASDAQ:ETNB) lost 6%, and Madrigal Pharmaceuticals Inc....
BioCentury | May 6, 2020
Product Development

Phase II data show Novo’s semaglutide leads the pack on NASH resolution

...endpoint, respectively. The best readouts on NASH resolution previously had been 24.7% for resmetirom from Madrigal Pharmaceuticals Inc....
BioCentury | Apr 16, 2020
Product Development

April 15 Quick Takes: TScan, Novartis team up on TCR therapies and a first for UroGen; plus Aligos, Leo, Madrigal, Merck

...assume responsibility for subsequent development. No protocol changes for Madrigal’s Phase III NASH, NAFLD studies Madrigal Pharmaceuticals Inc....
...Staff Ontruzant (Brand), SB3 (Compound #), biosimilar trastuzumab (Generic), Ontruzant (Other) Samsung Bioepis Co. Ltd. Merck & Co. Inc. Madrigal Pharmaceuticals Inc. Leo...
BioCentury | Apr 4, 2020
Finance

Pandemic upends norms for public fund-raising in election year

...analog AKR-001. But the stock move paled in comparison to valuations other NASH players like Madrigal Pharmaceuticals Inc....
BioCentury | Apr 12, 2019
Emerging Company Profile

Bright Angel: New hope against fungal resistance

...selectively target the fungal protein. For example, in 2015 Synta Pharmaceuticals Corp., which reverse-merged with Madrigal Pharmaceuticals Inc....
...sensitivity Companies and Institutions Mentioned Bright Angel Therapeutics Inc., Toronto, Ont. F2G Ltd., Eccles, U.K. Madrigal Pharmaceuticals Inc....
BioCentury | Apr 11, 2019
Clinical News

Gilead’s NASH combo data suggest benefit, safety

...data are competitive with MRI-PDFF data reported from a much larger trial of MGL-3196 from Madrigal Pharmaceuticals Inc....
...with MGL-3196 achieved at least a 30% reduction in liver fat at week 12 (see “Madrigal...
...while ACAC and THRB affect metabolism. Gilead was off $1.09 to $66.31 on Thursday, while Madrigal...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...Inc. (NASDAQ:RETA) 07/24/18 $248.4 $2,136.6 $1,667.2 -22% Immunomedics Inc. (NASDAQ:IMMU) 06/13/18 $317.4 $4,330.7 $2,711.6 -37% Madrigal Pharmaceuticals Inc....
BioCentury | Nov 3, 2018
Product Development

New partners for NASH

...of NASH. One target to watch is thyroid hormone receptor β. Viking Therapeutics Inc. and Madrigal Pharmaceuticals Inc....
...pair well with compounds that act on fibrosis, such as cenicriviroc or FXR agonists. But Madrigal...
...fibrosis sooner, resolving NASH may be sufficient for the liver to heal itself over time. Madrigal...
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...the basis of positive clinical news, such as HBV company Arrowhead Pharmaceuticals Inc., NASH companies Madrigal Pharmaceuticals Inc....
...NYSE:GSK), London, U.K. GW Pharmaceuticals plc (NASDAQ:GWPH), Cambridge, U.K. Illumina Inc. (NASDAQ:ILMN), San Diego, Calif. Madrigal Pharmaceuticals Inc....
BioCentury | Oct 5, 2018
Clinical News

Gilead's FXR agonist among NASH therapies highlighted ahead of AASLD

...pruritus with high-dose GS-9674 (14.3%) compared with low-dose GS-9674 (3.6%) and placebo (3.6%). Abstracts from Madrigal Pharmaceuticals Inc....
...thyroid hormone receptor β agonists. The companies will report updated data at AASLD. In May, Madrigal...
...relative reductions in liver fat at week 36 (37% vs 8.9% for placebo, p<0.0001) (see "Madrigal...
Items per page:
1 - 10 of 49
BioCentury | Jun 29, 2020
Regulation

Intercept: Surrogate endpoint not enough for FDA to approve NASH therapy

...more on Monday; NGM Biopharmaceuticals Inc. (NASDAQ:NGM) slipped 12%, 89bio Inc. (NASDAQ:ETNB) lost 6%, and Madrigal Pharmaceuticals Inc....
BioCentury | May 6, 2020
Product Development

Phase II data show Novo’s semaglutide leads the pack on NASH resolution

...endpoint, respectively. The best readouts on NASH resolution previously had been 24.7% for resmetirom from Madrigal Pharmaceuticals Inc....
BioCentury | Apr 16, 2020
Product Development

April 15 Quick Takes: TScan, Novartis team up on TCR therapies and a first for UroGen; plus Aligos, Leo, Madrigal, Merck

...assume responsibility for subsequent development. No protocol changes for Madrigal’s Phase III NASH, NAFLD studies Madrigal Pharmaceuticals Inc....
...Staff Ontruzant (Brand), SB3 (Compound #), biosimilar trastuzumab (Generic), Ontruzant (Other) Samsung Bioepis Co. Ltd. Merck & Co. Inc. Madrigal Pharmaceuticals Inc. Leo...
BioCentury | Apr 4, 2020
Finance

Pandemic upends norms for public fund-raising in election year

...analog AKR-001. But the stock move paled in comparison to valuations other NASH players like Madrigal Pharmaceuticals Inc....
BioCentury | Apr 12, 2019
Emerging Company Profile

Bright Angel: New hope against fungal resistance

...selectively target the fungal protein. For example, in 2015 Synta Pharmaceuticals Corp., which reverse-merged with Madrigal Pharmaceuticals Inc....
...sensitivity Companies and Institutions Mentioned Bright Angel Therapeutics Inc., Toronto, Ont. F2G Ltd., Eccles, U.K. Madrigal Pharmaceuticals Inc....
BioCentury | Apr 11, 2019
Clinical News

Gilead’s NASH combo data suggest benefit, safety

...data are competitive with MRI-PDFF data reported from a much larger trial of MGL-3196 from Madrigal Pharmaceuticals Inc....
...with MGL-3196 achieved at least a 30% reduction in liver fat at week 12 (see “Madrigal...
...while ACAC and THRB affect metabolism. Gilead was off $1.09 to $66.31 on Thursday, while Madrigal...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...Inc. (NASDAQ:RETA) 07/24/18 $248.4 $2,136.6 $1,667.2 -22% Immunomedics Inc. (NASDAQ:IMMU) 06/13/18 $317.4 $4,330.7 $2,711.6 -37% Madrigal Pharmaceuticals Inc....
BioCentury | Nov 3, 2018
Product Development

New partners for NASH

...of NASH. One target to watch is thyroid hormone receptor β. Viking Therapeutics Inc. and Madrigal Pharmaceuticals Inc....
...pair well with compounds that act on fibrosis, such as cenicriviroc or FXR agonists. But Madrigal...
...fibrosis sooner, resolving NASH may be sufficient for the liver to heal itself over time. Madrigal...
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...the basis of positive clinical news, such as HBV company Arrowhead Pharmaceuticals Inc., NASH companies Madrigal Pharmaceuticals Inc....
...NYSE:GSK), London, U.K. GW Pharmaceuticals plc (NASDAQ:GWPH), Cambridge, U.K. Illumina Inc. (NASDAQ:ILMN), San Diego, Calif. Madrigal Pharmaceuticals Inc....
BioCentury | Oct 5, 2018
Clinical News

Gilead's FXR agonist among NASH therapies highlighted ahead of AASLD

...pruritus with high-dose GS-9674 (14.3%) compared with low-dose GS-9674 (3.6%) and placebo (3.6%). Abstracts from Madrigal Pharmaceuticals Inc....
...thyroid hormone receptor β agonists. The companies will report updated data at AASLD. In May, Madrigal...
...relative reductions in liver fat at week 36 (37% vs 8.9% for placebo, p<0.0001) (see "Madrigal...
Items per page:
1 - 10 of 49